GTHX vs. TSVT, OMER, FHTX, PYXS, ALDX, QURE, PBYI, GBIO, DSGN, and OVID
Should you be buying G1 Therapeutics stock or one of its competitors? The main competitors of G1 Therapeutics include 2seventy bio (TSVT), Omeros (OMER), Foghorn Therapeutics (FHTX), Pyxis Oncology (PYXS), Aldeyra Therapeutics (ALDX), uniQure (QURE), Puma Biotechnology (PBYI), Generation Bio (GBIO), Design Therapeutics (DSGN), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical preparations" industry.
2seventy bio (NASDAQ:TSVT) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
In the previous week, 2seventy bio had 4 more articles in the media than G1 Therapeutics. MarketBeat recorded 5 mentions for 2seventy bio and 1 mentions for G1 Therapeutics. 2seventy bio's average media sentiment score of 0.98 beat G1 Therapeutics' score of 0.32 indicating that G1 Therapeutics is being referred to more favorably in the news media.
G1 Therapeutics has a net margin of -36.40% compared to G1 Therapeutics' net margin of -313.51%. G1 Therapeutics' return on equity of -67.59% beat 2seventy bio's return on equity.
2seventy bio has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, G1 Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.
2seventy bio presently has a consensus target price of $12.86, suggesting a potential upside of 167.86%. G1 Therapeutics has a consensus target price of $8.67, suggesting a potential upside of 91.32%. Given G1 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 2seventy bio is more favorable than G1 Therapeutics.
G1 Therapeutics received 281 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 65.81% of users gave G1 Therapeutics an outperform vote while only 60.98% of users gave 2seventy bio an outperform vote.
93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 24.2% of G1 Therapeutics shares are owned by institutional investors. 2.6% of 2seventy bio shares are owned by company insiders. Comparatively, 8.2% of G1 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
G1 Therapeutics has lower revenue, but higher earnings than 2seventy bio. G1 Therapeutics is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
Summary
2seventy bio beats G1 Therapeutics on 10 of the 19 factors compared between the two stocks.
Get G1 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
G1 Therapeutics Competitors List
Related Companies and Tools
